How it works:
Lenalidomide is a derivative of thalidomide with reduced toxicity and enhanced efficacy. It inhibits tumour proliferation, reduces angiogenesis, and stimulates immune cells including T lymphocytes and NK cells. It is used in monotherapy or as part of combination therapy protocols for multiple myeloma and related conditions.
Recommended for:
Patients with confirmed multiple myeloma
Individuals with MDS with 5q deletion
Those with mantle cell lymphoma
As a maintenance treatment after stem cell transplant
In relapsed/refractory cases unresponsive to standard therapy
Multiple myeloma
Myelodysplastic syndromes with 5q deletion
Mantle cell lymphoma
Maintenance therapy post-transplant
Lenalidomide is taken orally once daily at the same time with water. The dosage and duration of treatment are determined by a haematologist or oncologist based on disease stage and patient condition. Regular blood, liver, and coagulation monitoring is necessary during treatment.
Hypersensitivity to lenalidomide
Pregnancy and breastfeeding
Severe renal impairment without dose adjustment
High risk of thromboembolic complications
Children under 18 years
Neutropenia, thrombocytopenia
Nausea, constipation, diarrhoea
Headache, insomnia
Fatigue
Allergic reactions, skin rashes
Increased risk of venous thrombosis
